Related Experiment Video
Updated: Jun 29, 2025
10:24
Ischemic Tissue Injury in the Dorsal Skinfold Chamber of the Mouse: A Skin Flap Model to Investigate Acute Persistent Ischemia
Published on: November 17, 2014
16.8K
Topical Neuropeptide Y for Ischemic Skin Wounds
Tais Stangerup1, Lise Mette Rahbek Gjerdrum2,3, Michael Bzorek2
1Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, 2400 Copenhagen, Denmark.
International Journal of Molecular Sciences
|March 28, 2024
Summary
Topical neuropeptide Y (NPY) showed potential for enhancing blood vessel growth in ischemic wounds, though it did not accelerate healing rates. Further research is needed to optimize NPY dosage and delivery for wound healing applications.
Area of Science:
- Biomedical research
- Wound healing studies
- Neuropeptide research
Background:
- Ischemic wounds present a significant challenge in healing due to impaired blood supply.
- Neuropeptide Y (NPY) is a peptide with known roles in various physiological processes, including potential roles in tissue repair.
- Understanding the effects of NPY on wound healing is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To investigate the effects of topically applied neuropeptide Y (NPY) on the healing process of ischemic wounds.
- To evaluate the impact of NPY on wound closure rates, neovascularization, and inflammatory responses.
- To explore the expression of NPY receptor Y2R in ischemic wounds.
Main Methods:
- An animal model using Sprague Dawley rats with induced ischemic skin flap wounds was established and validated.
- Wounds were treated with NPY (0.025%), insulin-like growth factor-I (IGF-I, 0.0025%) as a positive control, or a hydrogel carrier alone.
- Wound healing was assessed over 14 days, with analysis including in situ hybridization for Y2R mRNA and histological examination for angiogenesis and inflammation.
Main Results:
- Neuropeptide Y (NPY) did not significantly increase wound healing rates compared to the control group (p = 0.907).
- Recombinant human insulin-like growth factor-I (rhIGF-I) significantly improved wound healing rates (p = 0.039).
- Histological analysis indicated a trend towards increased angiogenesis and inflammatory cell infiltration in NPY-treated wounds, suggesting potential for neovascularization.
Conclusions:
- Topical NPY shows potential for enhancing neovascularization in ischemic wound healing, but did not accelerate overall wound closure in this study.
- The NPY receptor Y2R was not detected in the wound tissue, suggesting other NPY receptor subtypes may be involved in its effects.
- Further optimization of NPY delivery systems and dosage is required to fully elucidate and harness its therapeutic potential in wound healing.
Related Concept Videos
01:19Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
01:28Phases of Wound Repair
6.0K
Following injury, the integrity of the injured tissues must be reestablished. For example, in skin tissue, wound repair involves coordination among resident skin cells, blood mononuclear cells, extracellular matrix, growth factors, and cytokines to complete the healing cascade.
Formation of Blood Clot
In case of deep injuries, trauma to blood vessels results in blood loss. In the meantime, phospholipids released from the ruptured endothelial cellular membrane are converted into arachidonic...
Formation of Blood Clot
In case of deep injuries, trauma to blood vessels results in blood loss. In the meantime, phospholipids released from the ruptured endothelial cellular membrane are converted into arachidonic...
6.0K